BiotechTube

Lenabasum 20 mg + Lenabasum 5 mg + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatomyositis

Conditions

Dermatomyositis

Trial Timeline

Dec 17, 2018 → Oct 5, 2021

NCT ID
NCT03813160

About Lenabasum 20 mg + Lenabasum 5 mg + Placebo

Lenabasum 20 mg + Lenabasum 5 mg + Placebo is a phase 3 stage product being developed by Corbus Pharmaceuticals for Dermatomyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT03813160. Target conditions include Dermatomyositis.

What happened to similar drugs?

0 of 2 similar drugs in Dermatomyositis were approved

Approved (0) Terminated (1) Active (1)
🔄DazukibartPfizerPhase 3
❌human immunoglobulin G + PlaceboCSLPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03813160Phase 3Completed

Competing Products

14 competing products in Dermatomyositis

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
26
M5049 high dose + PlaceboMerckPhase 2
27
BAF312 + PlaceboNovartisPhase 2
27
MEDI7734 + PlaceboAmgenPhase 1
29
Etanercept + PlaceboAmgenPhase 1
29
DazukibartPfizerPhase 3
47
Anti-Beta Interferon (PF-06823859)PfizerPhase 2
35
PF-06823859 low + Placebo Arm + PF-06823859 highPfizerPhase 2
35
TofacitinibPfizerPhase 1
29
EmapalumabSwedish Orphan BiovitrumPhase 2
42
human immunoglobulin G + PlaceboCSLPhase 3
32
Empasiprubart IVArgenxPhase 2
36
GLPG3667 + PlaceboGalapagosPhase 2
33
JBT-101 + PlaceboCorbus PharmaceuticalsPhase 2
17